Liu Lihong, Du Bo, Zhang Haiying, Guo Xiaofei, Zhou Zheng, Xiu Aihui, Liu Chang, Su Shiyu, Ai Hao
1Department of Gynecological Ward, The Third Affiliated Hospital, Jinzhou Medical University, Jinzhou, China.
Liaoning Provincial Key Laboratory of Follicle Development and Reproductive Health (Office of Science and Technology), Jinzhou, China.
Chin Med. 2018 Aug 29;13:46. doi: 10.1186/s13020-018-0201-1. eCollection 2018.
Polycystic ovary syndrome (PCOS) significantly affects women's health and well-being. To explore the pharmacological basis of the Erxian decoction (EXD) action in PCOS therapy, a network interaction analysis was conducted at the molecular level.
The active elements of EXD were identified according to the oral bioavailability and drug-likeness filters from three databases: traditional Chinese medicine system pharmacology analysis platform, TCM@taiwan and TCMID, and their potential targets were also identified. Genes associated with PCOS and established protein-protein interaction networks were mined from the NCBI database. Finally, significant pathways and functions of these networks were identified using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses to determine the mechanism of action of EXD.
Seventy active compounds were obtained from 981 ingredients present in the EXD decoction, corresponding to 247 targets. In addition, 262 genes were found to be closely related with PCOS, of which 50 overlapped with EXD and were thus considered therapeutically relevant. Pathway enrichment analysis identified PI3k-Akt, insulin resistance, Toll-like receptor, MAPK and AGE-RAGE from a total of 15 significant pathways in PCOS and its treatment.
EXD can effectively improve the symptoms of PCOS and our systemic pharmacological analysis lays the experimental foundation for further clinical applications of EXD.
多囊卵巢综合征（PCOS）严重影响女性的健康和幸福感。为了探索二仙汤（EXD）治疗PCOS的药理基础，在分子水平上进行了网络相互作用分析。
根据来自三个数据库（中药系统药理学分析平台、台湾中医药数据库和中药综合数据库）的口服生物利用度和类药性筛选标准，确定EXD的活性成分，并确定其潜在靶点。从NCBI数据库中挖掘与PCOS相关的基因并建立蛋白质-蛋白质相互作用网络。最后，使用基因本体论和京都基因与基因组百科全书分析确定这些网络的重要途径和功能，以确定EXD的作用机制。
从EXD汤剂中的981种成分中获得了70种活性化合物，对应247个靶点。此外，发现262个基因与PCOS密切相关，其中50个与EXD重叠，因此被认为具有治疗相关性。通路富集分析从PCOS及其治疗的总共15条重要通路中确定了PI3k-Akt、胰岛素抵抗、Toll样受体、MAPK和AGE-RAGE。
EXD可有效改善PCOS的症状，我们的系统药理学分析为EXD进一步的临床应用奠定了实验基础。
